Regeneron Pharmaceuticals Given Overweight Rating at Barclays (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “overweight” rating reiterated by analysts at Barclays in a research report issued to clients and investors on Friday, Analyst Ratings.Net reports. They currently have a $340.00 price target on the stock. Barclays’ price target points to a potential upside of 27.05% from the stock’s previous close.
In other Regeneron Pharmaceuticals news, SVP Peter Powchik sold 20,668 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $274.77, for a total value of $5,678,946.36. Following the completion of the sale, the senior vice president now directly owns 25,447 shares of the company’s stock, valued at approximately $6,992,072. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of other analysts have also recently weighed in on REGN. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $323.00 to $344.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. Separately, analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Friday, December 20th. Finally, analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $299.74.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 267.62 on Friday. Regeneron Pharmaceuticals has a one year low of $154.16 and a one year high of $319.83. The stock has a 50-day moving average of $278. and a 200-day moving average of $273.3. The company has a market cap of $26.287 billion and a P/E ratio of 38.94.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, November 5th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 39.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $3.83 EPS for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.